Practice-Based Research Networks: Integrating Clinical Data for Improved Pharmacoepidemiology
Tóm tắt
Pharmacovigilance is concerned with the detection, assessment, understanding, and prevention of adverse reactions to medicines. It is helpful to prevent undesired harm sustained by the patient due to inappropriate or unsafe use of medicinal agents. As the use of drugs and polypharmacy increase in prevalence, pharmacovigilance gains relevance and momentum. Practice-based research networks have the potential to enhance health research by promoting earlier detection of adverse events at a decreased level of cost. This article explores the recent evidence of an improved benefit of administering non-steroidal antiinflammatory drugs (NSAIDs) in the fasting state, and authors propose that an improved pharmacovigilance system is both needed and feasible provided records are adapted to a nationwide integration of pharmacoepidemiology data.
Tài liệu tham khảo
American Academy of Family Practice and Robert Graham Center. The patient centered medical home: history, seven core features, evidence and transformational change. Robert Graham Center: Washington, DC; 2007.
Curro FA, et al. Person-centric clinical trials: an opportunity for the good clinical practice (GCP)-practice-based research network. J Clin Pharmacol. 2013;53(10):1091–4.
Crabtree BF, et al. Summary of the national demonstration project and recommendations for the patient-centered medical home. Ann Fam Med. 2010;8:S80–90.
Moore A, et al. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol, and NSAIDs—systematic review. Br J Clin Pharmacol. 2015;80(3):381–8.
Ambulatory and Hospital Care Statistics Branch. National Hospital Ambulatory Medical Care Survey: 2011 Outpatient Department Summary Tables. 2011 [cited 2015 December, 2015]. http://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm.
World Health Organization. Cancer Pain Relief. Geneva: WHO; 1996.
Naranjo CA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.
Moore RA, Derry S, Wiffen PJ, Straube S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs—a systematic review. Br J Clin Pharmacol. 2015;80(3):381-8.
Wilkie P. A question of trust: the introduction of a national electronic patient record. Qual Prim Care. 2004;12:95–6.
Wise J. Less than 0.5% of safety incidents reported in 2008–9 came from general practice. Br Med J. 2010;340:c885.
FDA U.S. Department of Health and Human Services. Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. 2004.
FDA U.S. Department of Health and Human Services. Stagnation/Innovation—Critical Path Opportunities List. 2006.
FDA U.S. Food and Drug Administration. Mini-Sentinel. 2014 [cited 2016 June 2016]. http://www.mini-sentinel.org/.
FDA U.S. Food and Drug Administration. Sentinel Program Interim Assessment (FY 15). 2015.
Huang YL, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. Drug Saf. 2014;37(8):581–96.
Porter ME, Teisberg EO. How physicians can change the future of health care. JAMA. 2007;297(10):1103–11.